Stevens Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Stevens Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,547	Closed	-$545K	–	824
2018 Q3	$545K	Buy	2,547 +1,721	+208%	+$432K	0.02%	516
2018 Q2	$231K	Buy	+826	New	+$145K	0.01%	674
2015 Q3	–	Sell	-450	Closed	-$35K	–	1126
2015 Q2	$35K	Sell	450 -795	-64%	-$66.7K	﹤0.01%	975
2015 Q1	$85K	Sell	1,245 -559	-31%	-$47.9K	﹤0.01%	930
2014 Q4	$167K	Sell	1,804 -480	-21%	-$49.6K	0.01%	883
2014 Q3	$241K	Sell	2,284 -171	-7%	-$23.8K	0.01%	801
2014 Q2	$351K	Buy	2,455 +2,149	+702%	+$314K	0.01%	766
2014 Q1	$46K	Sell	306 -174	-36%	-$34.3K	﹤0.01%	1034
2013 Q4	$88K	Buy	480 +177	+58%	+$32.4K	﹤0.01%	970
2013 Q3	$67K	Buy	+303	New	+$64.5K	﹤0.01%	982

Other funds holding MDGL

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Stevens Capital Management's MDGL Position: Q4 2018 in Review

Stevens Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2018, closing a stake of 2,547 shares — an estimated $545K sold.

Stevens Capital Management first reported a position in MDGL in Q3 2013 and held it in 10 quarters. The position peaked at $545K in Q3 2018. 136 funds tracked by Wall St. Rank hold MDGL as of Q4 2018.

Stevens Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Stevens Capital Management sold 2,547 Madrigal Pharmaceuticals shares in Q4 2018, an estimated $545K.
Stevens Capital Management first reported a position in Madrigal Pharmaceuticals in Q3 2013 and held it in 10 quarters.
Stevens Capital Management's Madrigal Pharmaceuticals position peaked at $545K in Q3 2018.
136 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2018.

Based on Stevens Capital Management's 13F filing for Q4 2018, filed 6 Feb 2019.